Treatment with onvuzosiran (ADX-324), Adarx Pharmaceuticals’ experimental treatment for hereditary angioedema (HAE), was well tolerated and lowered kallikrein levels and the frequency of swelling attacks, according to interim data from a Phase 1/2 trial. The data were presented at the American Academy of Allergy, Asthma & Immunology annual scientific meeting,…